Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-PanTumor04: datopotamab deruxtecan combinations in urothelial cancer and non-small cell lung cancer
jRCT2031260507Phase 2Not yet recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Oct 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of datopotamab deruxtecan in transitional cell carcinoma (TCC) and non-small cell lung cancer (NSCLC) (6 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Number of participants with dose-limiting toxicities, Number of participants with treatment-emergent adverse events and 1 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
datopotamab deruxtecan
03
Conditions
transitional cell carcinoma (TCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031260507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260507.